India, Sept. 27 -- Mirum Pharmaceuticals, Inc. (MIRM), a rare disease company, is scheduled to host an investor call on September 28, 2026, to share topline results from the Phase 3 AZURE-1 study of Brelovitug in patients with Chronic hepatitis delta virus.
Chronic hepatitis delta virus (HDV) is the most severe form of viral hepatitis and occurs in people already infected with hepatitis B virus (HBV). The disease can progress rapidly to liver fibrosis, cirrhosis, liver cancer, and liver-related death.
Brelovitug is an investigational, fully human IgG1 monoclonal antibody designed to target the surface antigen of HDV and HBV. The drug is being developed to neutralize and remove viral particles and deplete surface-antigen -containing sub-vi...